
Ningbo Menovo Pharmaceutical Co., Ltd.
SSE:603538.SS
15.24 (CNY) • At close June 6, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,372.855 | 1,216.499 | 1,456.982 | 1,258.148 | 1,193.698 | 1,180.205 | 848.962 | 605.321 | 578.088 | 597.166 | 636.305 | 501.727 | 486.647 | 490.243 |
Cost of Revenue
| 925.127 | 873.793 | 872.795 | 788.928 | 758.573 | 727.629 | 572.499 | 399.065 | 361.51 | 400.47 | 426.153 | 329.113 | 326.233 | 331.588 |
Gross Profit
| 447.728 | 342.706 | 584.187 | 469.22 | 435.125 | 452.576 | 276.463 | 206.255 | 216.578 | 196.697 | 210.152 | 172.615 | 160.414 | 158.655 |
Gross Profit Ratio
| 0.326 | 0.282 | 0.401 | 0.373 | 0.365 | 0.383 | 0.326 | 0.341 | 0.375 | 0.329 | 0.33 | 0.344 | 0.33 | 0.324 |
Reseach & Development Expenses
| 99.652 | 95.297 | 98.155 | 88.313 | 62.05 | 52.96 | 39.208 | 32.024 | 29.078 | 38.122 | 30.553 | 22.605 | 25.984 | 0 |
General & Administrative Expenses
| 54.985 | 55.865 | 76.214 | 52.575 | 49.676 | 59.155 | 33.17 | 25.458 | 17.794 | 15.129 | 17.779 | 75.467 | 69.689 | 60.998 |
Selling & Marketing Expenses
| 42.532 | 33.015 | 50.624 | 29.29 | 14.34 | 21.331 | 18.875 | 17.3 | 12.955 | 12.955 | 13.444 | 9.302 | 8.607 | 8.923 |
SG&A
| 97.517 | 220.096 | 126.838 | 81.865 | 64.016 | 80.486 | 52.045 | 42.758 | 30.749 | 28.083 | 31.222 | 84.769 | 78.296 | 69.921 |
Other Expenses
| 157.965 | 8.565 | 116.378 | 110.818 | 109.909 | 102.789 | -5.798 | 0.49 | 11.515 | 10.26 | 2.911 | 5.435 | 2.214 | 2.037 |
Operating Expenses
| 355.134 | 323.958 | 341.371 | 280.996 | 235.976 | 236.235 | 171.249 | 131.607 | 117.56 | 119.557 | 108.993 | 87.803 | 80.074 | 71.445 |
Operating Income
| 92.594 | 18.748 | 405.323 | 187.906 | 215.54 | 189.734 | 112.557 | 63.881 | 98.454 | 91.504 | 91.609 | 84.807 | 75.189 | 92.185 |
Operating Income Ratio
| 0.067 | 0.015 | 0.278 | 0.149 | 0.181 | 0.161 | 0.133 | 0.106 | 0.17 | 0.153 | 0.144 | 0.169 | 0.155 | 0.188 |
Total Other Income Expenses Net
| -5.63 | -10.79 | -21.162 | -7.614 | -2.352 | -2.487 | -5.798 | 0.49 | 4.66 | 9.545 | 2.577 | 5.126 | -1.829 | 1.348 |
Income Before Tax
| 86.964 | 7.958 | 384.161 | 180.292 | 214.663 | 187.247 | 106.759 | 64.371 | 105.172 | 101.049 | 94.186 | 89.933 | 77.198 | 93.533 |
Income Before Tax Ratio
| 0.063 | 0.007 | 0.264 | 0.143 | 0.18 | 0.159 | 0.126 | 0.106 | 0.182 | 0.169 | 0.148 | 0.179 | 0.159 | 0.191 |
Income Tax Expense
| 10.915 | -8.225 | 16.547 | 22.222 | 41.607 | 26.447 | 1.697 | 14.418 | 20.049 | 19.276 | 15.695 | 16.269 | 12.84 | 14.818 |
Net Income
| 66.807 | 11.586 | 338.856 | 142.526 | 155.963 | 150.905 | 96.349 | 44.677 | 78.843 | 77.02 | 72.73 | 69.005 | 60.61 | 69.335 |
Net Income Ratio
| 0.049 | 0.01 | 0.233 | 0.113 | 0.131 | 0.128 | 0.113 | 0.074 | 0.136 | 0.129 | 0.114 | 0.138 | 0.125 | 0.141 |
EPS
| 0.32 | 0.05 | 1.61 | 0.69 | 0.76 | 0.75 | 0.48 | 0.24 | 0.52 | 0.51 | 0.48 | 0.46 | 0.4 | 0.64 |
EPS Diluted
| 0.32 | 0.05 | 1.49 | 0.66 | 0.76 | 0.73 | 0.47 | 0.24 | 0.52 | 0.51 | 0.48 | 0.46 | 0.4 | 0.64 |
EBITDA
| 269.12 | 155.451 | 498.482 | 301.579 | 321.396 | 275.055 | 158.393 | 101.17 | 116.145 | 111.398 | 128.204 | 84.812 | 87.424 | 82.816 |
EBITDA Ratio
| 0.196 | 0.128 | 0.342 | 0.24 | 0.269 | 0.233 | 0.187 | 0.167 | 0.201 | 0.187 | 0.201 | 0.169 | 0.18 | 0.169 |